Endpoints News – Eli Lilly is diving into the messenger RNA arena, signing off on a heavily back-ended $1.8 billion deal with Germany’s CureVac to develop up to 5 new-wave cancer vaccines.
CureVac is getting $100 million in cash to kick off the collaboration, split between an upfront payment and equity stake. Then there’s a package of $1.7 billion in milestones on the table.
In turn CureVac will be tasked with designing a slate of new cancer vaccines that uses mRNA tech to instruct the human immune system to target a specific set of neoantigens. While past cancer vaccines have generally proven to be ineffective though safe, a number of developers have been hunting down specific patient antigens that can be leveraged for much more precise targeting — with a greater likelihood of success.
Read more at Endpoints News.